![photo of combination chemo and immunotherapy](https://img.webmd.com/dtmcms/live/webmd/consumer_assets/site_images/articles/health_tools/questions_to_ask_doctor_about_egfr_positive_nsclc_slideshow/1800ss_science_source_rm_combination_chemo_and_immunotherapy.jpg)
His tumor had a specific genetic makeup known as mismatch repair-deficient, present in 5% to 10% of all rectal cancer patients, meaning he might qualify for a cutting-edge immunotherapy.
His tumor had a specific genetic makeup known as mismatch repair-deficient, present in 5% to 10% of all rectal cancer patients, meaning he might qualify for a cutting-edge immunotherapy.